An inhibitory alternative splice isoform of Toll-like receptor 3 is induced by type I interferons in human astrocyte cell lines

Jin-Won Seo¹, Eun-Jeong Yang¹, Se Hoon Kim² & In-Hong Choi¹,*

¹Department of Microbiology, Institute for Immunology and Immunological Diseases, and Brain Korea 21 PLUS Project for Medical Science, ²Department of Pathology, Yonsei University College of Medicine, Seoul 03722, Korea

INTRODUCTION

Toll-like receptor 3 (TLR3) recognizes viral double-stranded RNA. It stimulates pro-inflammatory cytokine and interferon production. Here we reported the expression of a novel isoform of TLR3 in human astrocyte cell lines whose message is generated by alternative splicing. The isoform represents the N-terminus of the protein. It lacks many of the leucine-rich repeat domains, the transmembrane domain, and the intracellular Toll/interleukin-1 receptor domain of TLR3. Type I interferons (interferon-α and interferon-β) induced the expression of this isoform. Exogenous overexpression of this isoform inhibited interferon regulatory factor 3, signal transducers and activators of transcription 1, and Inhibitor of kappa B α signaling following stimulation. This isoform of TLR3 also inhibited the production of chemokine interferon-γ-inducible protein 10.

Our study clearly demonstrated that the expression of this isoform of TLR3 was a negative regulator of signaling pathways and that it was inducible by type I interferons. We also found that this isoform could modulate inflammation in the brain.

RESULTS

An isoform of TLR3 is expressed in human astrocyte cell lines

To investigate whether TLR3 has additional splice variants, we examined the expression level of TLR3 transcripts using different sets of primers corresponding to the 5′- or the 3′-UTR. A172 cells expressed a novel isoform of TLR3 that contained different cellular response (4-6). Within distinct immunological milieu of the brain, TLR3 has been found to be necessary for the secretion of TNF-α, IL-12p40, and IL-6 in murine microglial cells after being stimulated by polyinosinic-polycytidylic acid (poly(I:C)) (7). In viral infections such as experimental infection with simian immunodeficiency virus and human immunodeficiency virus encephalitis, TLR3 expression is upregulated, leading to the induction of active innate immune responses in the brain (8). Following intracerebroventricular administration of poly(I:C) to mimic viral infection in the central nervous system, TLR3 signaling is activated, resulting in contextual memory and enhanced susceptibility to seizures (9, 10). Similar effects of viral infection on brain function have been reported in encephalitis and associated epileptic activity (11-13). These reports suggest that inflammation as innate immune response is important in neurological disorders and in anti-viral defenses.

Astrocytes perform a variety of physiological functions such as forming the blood-brain barrier, transporting nutrients, and maintaining ion balances for the normal physiology of the brain. In addition, astrocytes play an important role in diseases related to neuro-inflammation (14, 15). Astrocytes express numerous PRRs to allow for the recognition of diverse pathogen-associated molecular patterns (PAMPs) (16-18). We have previously reported that TLR3 is expressed in astrocytes and that its activation induces the expression of IL-6 (19). We have reported that an isoform of TLR3 lacking 192 bp is produced by alternative splicing in primary astrocytes and astrocyte cell lines (20). However, the mechanistic role of this isoform is unclear. In this study, we report a novel isoform of TLR3 that is induced by type I IFNs in astrocyte cell lines. It downregulated poly(I:C)-induced TLR3 signaling. This isoform might have an immune-modulatory function during brain inflammation and other pathological conditions.
An inhibitory TLR3 isoform is inducible by IFNs
Jin-Won Seo, et al.

Fig. 1. Identification of a novel splice-isoform of human TLR3 in A172 cells. (A) Schematic diagram of wild type TLR3 gene with depiction of primer sets used for RT-PCR. (B) RT-PCR analysis of the wild type TLR3 and its novel isoform using mRNA from A172 cells. (C) Amino acid sequences of TLR3 and the novel TLR3 isoform. (D) cDNA and protein sequences of wild type TLR3 and its novel isoform. Numbers on the left indicate nucleotides, and numbers in parentheses on the right indicate amino acids. The asterisks indicate the portion missing from the isoform. The TLR3 isoform is related to wild type TLR3 by alternative splicing. The splice donor (gt) and acceptor (ag) sequences at positions 966-967 and 2,586-2,587, respectively, are in boxes. The splicing event introduces a frame-shift mutation and a stop codon “TGA” at region of 2,621-2,623 bp, resulting in translation of a 299 amino acid polypeptide (Fig. 1D).

TLR3 isoform differed from those of the TLR3 wild type as a result of a frame-shift introduced by alternative splicing. The alternative splicing occurred between the donor “GT” (region of 966-967 bp) and acceptor “AG” (region of 2,586-2,587 bp), introducing a frame-shift mutation and a stop codon “TGA” at region of 2,621-2,623 bp, resulting in translation of a 299 amino acid polypeptide (Fig. 1D).
An inhibitory TLR3 isoform is inducible by IFNs
Jin-Won Seo, et al.

IFN-α/β increases the transcript of the novel isoform of TLR3 in astrocyte cell lines
Upon viral infection, TLR3 will produce type I IFNs via activating IRF3. To assess the effect of type I IFNs on the transcription of the novel isoform of TLR3, A172 and NHA cells were treated with IFN-α or IFN-β. As a result, the transcription of this novel isoform of TLR3 was increased (Fig. 2A) after treatment with IFN-α or IFN-β. The transcript of this novel isoform of TLR3 was detectable starting at 3 h post treatment. Its level was increased until 24 h after IFN-β treatment (Fig. 2B).

Overexpression of the novel isoform of TLR3 inhibits TLR3 signaling
Next, we determined whether the expression of the novel TLR3 isoform would influence TLR3 signaling pathway induced by poly(I:C). Our results revealed that the poly(I:C) treatment induced phosphorylation of interferon regulatory factor 3 (IRF3), Inhibitor of kappa B α (IkBα), and signal transducers and activators of transcription 1 (STAT1) via TLR3 signaling in the control group (Fig. 3). When the isoform was exogenously overexpressed, phosphorylation levels of IRF3, IkBα, and STAT1 were significantly reduced compared to the mock transfection control (Fig. 3).

Expression of the novel isoform of TLR3 affects the production of interferon-γ-inducible protein 10 (IP-10)
To determine the effect of expression of the novel isoform of TLR3 on the secretion of antiviral chemokines, IP-10 was se-
dose-dependent manner in cells exogenously overexpressing STAT1 (Fig. 3), the production of IP-10 was decreased in a TLR3 JAK/STAT pathway. Consistent with the inhibitory effect of experimental autoimmune encephalomyelitis (27, 28). Recent some autoimmune diseases such as multiple sclerosis and ex-astrocytes. TLR3 is active in anti-viral immune responses and ments of TLR9 can inhibit TLR9 signaling (25, 26).

neutral pH-dependent proteases, produced N-terminal frag-
tions. For example, protease-mediated regulation of TLR depends on the type of protease that is active. When TLR9 is cleaved by acidic pH-dependent protease such as cathepsins or asparagine endopeptidase, pro-
tein product negatively regulated TLR3 activity. Therefore, in this study, we found a novel isoform of TLR3 generated by alternative splicing in astrocyte cell lines. This novel isoform has only LRRs 1-10. It lacks the entire transmembrane and cytoplasmic TIR domains. The expression of this isoform was induced by the treatment with type I IFNs. Interestingly, when the isoform was exogenously overexpressed, poly(I:C)-induced TLR3 activation was significantly reduced. Moreover, the secretion of IFN-responsive chemokine IP-10 was decreased in cells overexpressing this isoform. These negative regulatory effects of this TLR3 isoform may be caused by competition for ligand binding because this TLR3 isoform has dsRNA binding sites (LRR1 and LRR3), whereas it lacks the cytoplasmic TIR domain required for signal transduction (25, 32).

In summary, our results demonstrated that the expression of a novel isoform of TLR3 was induced by type I IFNs and that its protein product negatively regulated TLR3 activity. Therefore, this novel isoform of TLR3 might have immune-modulatory function in brain inflammation and some pathological condi-
tions.

MATERIALS AND METHODS
Reagents
Poly(I:C) was purchased from Invivogen (San Diego, CA, USA). Recombinant human IFN-α and IFN-β were purchased from Pro Spec (East Brunswick, NJ, USA). Anti-phospho-IRF3 (Ser396), anti-IRF-3, anti-phospho-IκBα (Ser32), anti-IκBα, and anti-phospho-STAT1 (Tyr701) antibodies were purchased from Cell Signaling Technology Inc. (Danvers, MA, USA). Anti-tubulin antibody was purchased from Abcam (Cambridge, MA, USA).

Cell culture
Human glioblastoma cell line A172 was obtained from ATCC and cultured in DMEM medium containing 10% fetal bovine serum (FBS) and penicillin-streptomycin (100 units/ml and 100 µg/ml, respectively) at 37°C in a humidified 5% CO₂ incubator. Normal human astrocyte (NHA) cells were cultured in DMEM/F-12 medium containing 10% FBS, 10 µg/ml of blasticidin, 0.2 µg/ml of puromycin, and penicillin-streptomycin (100 units/ml and 100 µg/ml, respectively) at 37°C in a humidified 5% CO₂ incubator.

RT-PCR
A172 cells (1 × 10⁶ cells per well) were treated with or without IFN-α or IFN-β (500 units/ml, respectively) for 24 h. NHA cells (5 × 10⁵ cells per well) were treated with IFN-β (500 units/ml). After incubation, total RNA was isolated from A172 or NHA cells using RNeasy Mini kit (Qiagen, Santa Claris, CA, USA). A total of 2 µg of total RNA was used to synthesize cDNA with random primers and M-MLV Reverse Transcriptase (Invitrogen). RT-PCR was performed using ex Taq polymerase

http://bmbreports.org
(Takara, Tokyo, Japan). The following primers were used for RT-PCR: F (5'-GAA AGG GTA CCA GTC ATC CAA-3'), R1 (5'-CAA AAA TAG GCC TGA AAT AAG-3'), R2 (5'-TAT GAA TAA ACA AAT TAT AAC AC-3'), R3 (5'-TTT CTC CTT TGC TAA TTT AAT-3'). The following PCR conditions were used: denaturation at 94°C for 1 min, annealing at 50°C for 30s, and extension at 72°C for 2 min. After 30 cycles, an additional extension at 72°C for 10 min was performed. These primers were designed based on human TLR3 mRNA sequences obtained from GenBank (accession No. NM_003265.2).

Cloning of the TLR3 isoform
Total RNA was isolated from A172 cells (1 x 10⁶ cells) using RNeasy Mini kit (Qiagen). A total of 3 μg of total RNA was used for cDNA synthesis with M-MLV Reverse Transcriptase (Invitrogen) using forward (5'-G GCC ATG GAG GCC ATG AGA CAG ACT TTG CCT TGT ATC-3') and reverse (5'-CCG TTC TCA ATA GCT TGT CTA GCA GTA TGT-3') primers. A vector for TLR3 isoform expression was constructed by inserting PCR-amplified cDNA digested with SfiI and EcoRI into pCMV-Myc vector (Clontech, Palo Alto, CA, USA).

Western blot
A172 cells were cultured in 6-well plates at 3 x 10⁵ cells per well and transiently transfected with 1 μg of pCMV-Myc (mock) or pCMV-Myc/TLR3 isoform for 24 h. Cells were stimulated with 25 μg/ml of poly(I:C) for indicated time periods. After stimulation, cells were harvested and lysed with lysis buffer (150 mM sodium chloride, 1.0% NP-40, 50 mM Tris, pH 8.0) containing protease and phosphatase inhibitor cocktails (GenDEPOT, TX, USA). Cell lysates were centrifuged and supernatants were stored at -80°C. Protein concentrations of lysates were measured using Bradford protein assay. Fifty micrograms of each protein sample was separated by 12% SDS-PAGE and transferred onto a nitrocellulose membrane (GE Healthcare, Waukesha, WI, USA). Membranes were incubated with anti-phospho-IRF3 (Ser 398), anti-IRF-3, anti-phospho-IκBα, anti-p38, anti-phospho-STAT1 (Tyr 701), or anti-tubulin antibody. Protein bands were detected using a West-Save western blot detection kit (Ab Frontier, Seoul, Korea).

Enzyme-linked immunosorbent assay (ELISA)
A172 cells were cultured in 6-well plates at 3 x 10⁵ cells per well and transiently transfected with 0.3 μg of pCMV-Myc/TLR3 isoform using Fugene 6 reagent according to instructions of the manufacturer (Roche, Basel, Switzerland). Mock vector (pCMV-Myc) was transfected at 0.3 μg per well. After 24 h, cells were stimulated with 10 μg/ml of poly(I:C) for 12 h. Culture supernatants were harvested and stored at -80°C. ELISA was performed with a human cytokine IP-10 assay kit (BD Bioscience, San Jose, CA, USA). The optical density (O.D.) at 450 nm was determined.

Statistical analysis
One-way ANOVA was performed for statistical analysis using PRISM version 5.01 (GraphPad Software, Inc., La Jolla, CA, USA). P < 0.05 was considered statistically significant.

ACKNOWLEDGEMENTS
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2012R1A4A1029061).

REFERENCES
1. Matsumoto M, Oshiumi H and Seya T (2011) Antiviral responses induced by the TLR3 pathway. Rev Med Virol 21, 67-77
2. Hosokawa Y, Hosokawa I, Shindo S, Ozaki K and Matsuoe T (2013) TLR3 agonist enhances CC chemokine ligand 20 production in IL-1beta-stimulated human gingival fibroblasts. Cell Immunol 283, 8-11
3. Yu M and Levine SJ (2011) Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses. Cytokine Growth Factor Rev 22, 63-72
4. Farina C, Krumbholz M, Giese T, Hartmann G, Aloisi F and Meinl E (2005) Preferential expression and function of Toll-like receptor 3 in human astrocytes. J Neuroimmunol 159, 12-19
5. Olson JK and Miller SD (2004) Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 173, 3916-3924
6. Matsumoto M, Funami K, Tanabe M et al (2003) Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 171, 3154-3162
7. Town T, Jeng D, Alexopoulos L, Tan J and Flavell RA (2006) Microglia recognize double-stranded RNA via TLR3. J Immunol 176, 3804-3812
8. Suh HS, Brosnan CF and Lee SC (2009) Toll-like receptors in CNS viral infections. Curr Top Microbiol Immunol 336, 63-81
9. Galic MA, Riazi K, Henderson AK, Tsutsumi S and Pittman QJ (2009) Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats. Neurobiol Dis 36, 343-351
10. Riazi K, Galic MA and Pittman QJ (2010) Contributions of peripheral inflammation to seizure susceptibility: cytokines and brain excitability. Epilepsy Res 89, 34-42
11. Dakovic I, da Graca Andradá M, Folha T et al (2014) Clinical features of cerebral palsy in children with symptomatic congenital cytomegalovirus infection. Eur J Paediatr Neurol 18, 618-623
12. Singh TD, Fugate JE, Hocker SE and Rabinstein AA (2015) Postencephalitic epilepsy: clinical characteristics and predictors. Epilepsia 56, 133-138
13. Wilson JC, Toovey S, Jick SS and Meier CR (2014) Previously diagnosed influenza infections and the risk of developing epilepsy. Epidemiol Infect, 1-8
14. Sofroniew MV and Vinters HV (2010) Astrocytes: biology

An inhibitory TLR3 isoform is inducible by IFNs
Jin-Won Seo, et al.

http://bmbreports.org
An inhibitory TLR3 isoform is inducible by IFNs.

Jin-Won Seo, et al.

15. Le OT, Nguyen TT and Lee SY (2014) Phosphoinositide turnover in Toll-like receptor signaling and trafficking. BMB Rep 47, 361-368

16. Costello DA and Lynch MA (2013) Toll-like receptor 3 activation modulates hippocampal network excitability, via glial production of interferon-beta. Hippocampus 23, 696-707

17. Pan LN, Zhu W, Li Y et al (2014) Astrocytic Toll-like receptor 3 is associated with ischemic preconditioning-induced protection against brain ischemia in rodents. PLoS One 9, e99526

18. Nakajima A, Ibi D, Nagai T, Yamada S, Nabeshima T and Yamada K (2014) Induction of interferon-induced transmembrane protein 3 gene expression by lipopolysaccharide in astrocytes. Eur J Pharmacol 745, 166-175

19. Kim H, Yang E, Lee J et al (2008) Double-stranded RNA mediates interferon regulatory factor 3 activation and interleukin-6 production by engaging Toll-like receptor 3 in human brain astrocytes. Immunology 124, 480-488

20. Yang E, Shin JS, Kim H et al (2004) Cloning of TLR3 isoform. Yonsei Med J 45, 359-361

21. Sepulveda FE, Maschalidi S, Colisson R et al (2009) Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity 31, 737-748

22. Marshak-Rothstein A (2006) Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6, 823-835

23. Krieg AM and Vollmer J (2007) Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 220, 231-269

24. Chockalingam A, Cameron JL, Brooks JC and Leifer CA (2011) Negative regulation of signaling by a soluble form of toll-like receptor 9. Eur J Immunol 41, 2176-2184

25. Ewald SE, Engel A, Lee J, Wang M, Bogyo M and Barton GM (2011) Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. J Exp Med 208, 643-651

26. Manoury B (2011) TLR9 regulation by proteolysis: a friend or a foe. Eur J Immunol 41, 2142-2144

27. Miranda-Hernandez S and Baxter AG (2013) Role of toll-like receptors in multiple sclerosis. Am J Clin Exp Immunol 2, 75-93

28. Touil T, Fitzgerald D, Zhang GX, Rostami A and Gran B (2006) Cutting Edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta. J Immunol 177, 7505-7509

29. Murakami Y, Fukui R, Mutoi Y et al (2014) Roles of the cleaved N-terminal TLR3 fragment and cell surface TLR3 in double-stranded RNA sensing. J Immunol 193, 5208-5217

30. Garcia-Cattaneo A, Gobert FX, Muller M et al (2012) Cleavage of Toll-like receptor 3 by cathepsins B and H is essential for signaling. Proc Natl Acad Sci U S A 109, 9053-9058

31. Toscano F, Estornes Y, Virard F et al (2013) Cleaved/associated TLR3 represents the primary form of the signaling receptor. J Immunol 190, 764-773

32. Qi R, Singh D and Kao CC (2012) Proteolytic processing regulates Toll-like receptor 3 stability and endosomal localization. J Biol Chem 287, 32617-32629